普米克令舒联合沐舒坦雾化吸入治疗AECOPD的疗效观察

摘要

Objective To study the clinical efficacy of aerosol inhalation therapy of Pulmicort Respules combined with Muco-solvan on acute chronic obstructive pulmonary disease ( AECOPD). Methods 80 cases of AECOPD were randomly divided into two groups, a treatment group of 42 and a control group of 38. The patients in the treatment group were treated with aerosol inhalation therapy of Pulmicort Respules 1 mg combined with Mucosolvan 15 mg based on routine treatment including supplemental oxygen, Solu-Medrol, the-ophylline, anti-infection. And the control group was treated by routine treaunen only. Then the clinical manifestations, blood gas analysis and FEV1 were determined 5 days after treatment. Results There were significant differences in PaO2, PaCO2 and FEV1% between the two groups before and after treatment (P < 0. 05 ). Conclusion Aerosol inhalation therapy of Pulmicort Respules combined with Mucosolvan could relieve the symptom of patients with AECOPD, correct hypoxia and carbon dioxide retention and improve pulmonary function.%目的 观察普米克令舒及沐舒坦联合雾化吸入治疗对于慢性阻塞性肺疾病急性加重期(AECOPD)患者的疗效.方法 将AECOPD患者80例随机分为两组,治疗组42例,对照组38例,对照组给予抗炎、解痉、平喘等治疗；治疗组在常规治疗的基础上给予普米克令舒及沐舒坦雾化吸入,每天2次,治疗5天后两组之间症状改善、血气分析及肺功能进行比较.结果 用药治疗5天后,两组患者在症状体征改善的有效率、二氧化碳、氧分压及肺功能两组之间比较差异有统计学意义(P＜0.05).结论 普米克令舒联合沐舒坦雾化吸入治疗能够有效的缓解患者的症状,纠正低氧及二氧化碳潴留、改善患者的肺功能.